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Abstract Purpose Parenteral administration of low-
molecular-weight heparins (LMWHs) and unfractionated
heparin (UFH) resulted effective in improving the symp-
toms of experimental colitis in rat. Today, there is little
information about their activity by intracolonic instillation.
The scope of this study was to evaluate the ability of CB-
01-05 (a LMWH with a mean molecular weight of about
5,700), compared to a series of other LMWHs and to UFH,
directly instilled into the distal colon of the rat, to ame-
liorate dinitrobenzene (DNB)-induced experimental colitis.
Method Adult male Wistar rats underwent colitis induction
by intracolonic instillation of DNB. Starting 24 h after
colitis induction, CB-01-05 (0.005–0.9 mg), other LMWHs
(0.3–0.6 mg), and UFH (0.6 mg) were instilled, by rectal
route, into the distal colon once a day for three consecutive
days. On the day following the last administration, the
animals were sacrificed and the distal colon was isolated,
weighed, macroscopically examined, and processed for
histology. Additional experiments in rat splenocytes, per-
formed in order to elucidate the anti-inflammatory
mechanisms of CB-01-05, were performed. Results Among
the tested items, only CB-01-05 at doses ranging from 0.2
to 0.9 mg was significantly effective in reducing colon
weight increase and in improving both the mucosal dam-
aged area and the histological score. The other LMWHs
resulted far less effective, showing decreasing activity
closely related with the decrease of their molecular weight,
thus demonstrating their biological nonequivalence. CB-
01-05 resulted also more active than UFH. CB-01-05 was
shown to interfere with cytokines production by rat
splenocytes, mainly inhibiting interferon (IFN)-c expres-
sion. Conclusions CB-01-05 instilled into the colon is well
tolerated, has strong anti-inflammatory effect on DNB-
induced colitis in rat, and is the most effective agent among
other LMWHs and UFH. These results suggest that the
anti-inflammatory activity of CB-01-05, together with its
topical administration, could represent a new approach in
the management of ulcerative colitis.
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Introduction
Inflammatory bowel disease (IBD) encompasses ulcerative
colitis (UC) and Crohn’s disease (CD), both of which are
chronic, recurrent, nonspecific intestinal inflammatory pro-
cesses of unknown aetiology. Current medical treatment of
IBD, titrated according to the severity of the disease and to
the individual response, includes 5-aminosalicylic acid
(ASA) derivatives, corticosteroids, immunosuppressants,
and most recently biologic agents mainly targeted against
tumor necrosis factor (TNF)-a. Among the emerging treat-
ments for ulcerative colitis, the parenteral administration of
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low-molecular-weight heparins (LMWHs), i.e., dalteparin,
enoxaparin, nadroparine, reviparin, deligoparin, and tinzap-
arin, was judged clinically useful by some authors [1–3], but
questioned by others [4–8]. The administration of LMWHs
by oral route has recently been attempted, resulting safe and
effective in corticosteroid-resistant UC patients [9]. In spite
of these encouraging results, this route of administration did
not gain credit due to the conviction that LMWHs admin-
istered in conventional oral formulations are ineffective
since they are inactivated in the upper gastrointestinal tract,
thus not reaching therapeutic concentrations in the colon.
The development of a novel oral extended-release technol-
ogy (MMXTM, Cosmo Technologies Ltd., Dublin) able to
deliver active substances directly on the mucosal surface of
the colon, while avoiding all limitations closely related to
the conventional oral formulations, offers a promising tool
for IBD treatment. This concept has been recently supported
by the observation that oral administration of enoxaparin-
loaded microspheres proved to be effective in experimen-
tally induced colitis in mice [10]. The first question to be
answered in developing a new oral, colon-release formula-
tion containing LMWHs is to ascertain the real topical
activity of the substances arriving in direct contact with the
inflamed mucosa of the colon. A preliminary requirement to
solve this issue is the availability of well-proven and
reproducible animal models of colonic inflammation. The
experimental colitis in rodents, induced by various chemical
substances, i.e., dinitrobenzene sulfonic acid (DNB), trini-
trobenzene sulfonic acid (TNB), dinitrofluorobenzene
(DNFB), dextran sulfate sodium (DSS), oxazolone (OXA),
iodoacetamide, or acetic acid, is considered a suitable model
resembling the human IBD [10–17]. In this experimental
model the parenteral administration of unfractionated hep-
arin (UFH) and some LMWHs (i.e., enoxaparin, dalteparin)
resulted effective [10–13, 16, 17]. Nevertheless, there is
little information about their activity after intracolonic
instillation [10]. In this paper we report the activity of CB-
01-05 (parnaparin sodium), a LMWH with a mean molec-
ular weight of about 5,700, compared to a series of other
LMWHs and to UFH, administered into the lumen of the
colon in DNB-induced colitis in rat.
Materials and Methods
Animals
Adult male Wistar rats (Charles River Italy) of about 200–
250 g body weight were used in our experiments. Animals
were kept in temperature- and light-controlled rooms,
maintained at a constant temperature of approximately
24C and 12 h of light/day. Animals were fed with stan-
dard animal pellets (Mucedola, Italy) and tap water ad
libitum. The experiments were approved by the local
Institutional Ethical Committee, and were performed in
agreement with the Italian Legislative Decree 116/
27.01.1992 concerning the protection of animals used for
experimental purpose or other scientific scope.
Products Used and Their Characteristics
CB-01-05, the other LMWHs, and UFH, used in our
experiments, are listed in Table 1, showing the internal
product code, batch number, mean molecular weight, and
specific activity.
Induction of DNB-Colitis and Topical Treatment
Groups of 8–10 rats were used. Under light ether anaes-
thesia, each animal was intracolonically instilled with
30 mg of DNB dissolved in 0.25 ml of ethanol 50%. The
administration of the irritant was made by a catheter (outer
diameter 0.3 mm) placed about 7 cm proximal to the anus.
After DNB instillation, 0.5 ml of air was insufflated, after
which the catheter was removed. CB-01-05 (0.005–
0.9 mg), LMWH-A, B, C (0.3–0.6 mg), and UFH (0.6 mg)
were dissolved in 0.25 ml of saline containing sodium
cholate 1% and were administered by intracolonic route,
with the same procedure described for the administration of
the irritant. The treatment was repeated for three consec-
utive days, 24 h apart, beginning on the day after colitis
induction. Control groups of animals were instilled with the
vehicle only. On the day following the last colonic instil-
lation (day 5 of experiment), the animals were euthanized
by ether inhalation.
Macroscopic Evaluation of Colonic Damage
Immediately after sacrifice, the rats were laparatomized
and the intestine was exteriorized. The colon was isolated,
carefully cleaned from mesenterium, vessels, and fat, and
was placed unstretched on a ruler. A 10-cm segment of the
distal colon was cut and was weighed after gentle rinsing of
the lumen with saline. Then, the isolated portion of the
Table 1 Products used and their characteristics




CB-01-05 92308 5,760 104.9 anti-Xa
LMWH-A G0101 5,304 96.1 anti-Xa
LMWH-B 93284 3,110 66.9 anti-Xa
LMWH-C S0108 2,601 43.1 anti-Xa
UFH 93342 – 197.4 anticlotting
LMWH, low-molecular-weight heparin; UFH, unfractionated heparin
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colon was longitudinally opened by button-scissors and
pinned down on a cork-table with the mucosal surface
oriented to the observer. The area of the damaged mucosa
(MDA) was measured by a caliper and was expressed in
mm2 [13].
Histological Evaluation of Colonic Damage
The histological score (HS) was calculated on the damaged
areas of the colonic samples which were fixed in phosphate
buffered formalin, embedded in paraffin wax, 5-lm-thick
sectioned, and stained with haematoxylin–eosin. An
experienced blinded observer evaluated the specimens.
Histological scoring was determined by examining each
specimen for the following features of damage: depth and
extent of necrosis, presence and extent of inflammation,
and fibrosis. Each item was scored according to the severity
(0 = no damage, to 4 = extensive/severe damage), and the
scores for each item were added up for each specimen to
obtain the total score, as described by Dotan et al. [13].
Determination of Cytokines Production by Rat
Splenocytes
In order to investigate the possible role of CB-01-05 in
inflammation, the effect of CB-01-05 and UFH on cyto-
kines production by rat splenocytes was also assessed.
Spleen mononuclear cells were collected from healthy
untreated rats. The cells, plated (2 9 106) in triplicate in
flat-bottomed microtiter plates (Costar, Cambridge, MA),
were grown in complete culture medium (RPMI 1640, 10%
heat-inactivated foetal calf serum (Invitrogen, Milano,
Italy), 2 nM/ml L-glutamine, 100 U/ml penicillin, and
100 lg/ml streptomycin). The cells were incubated for
72 h, at 37C with 5% CO2, in the presence or in absence
of 4 lg/ml Con-A or 2 lg/ml phytohemagglutinin
(PHA) + 0.3 lg/ml lipopolysaccharide (LPS) (Sigma
Chemical Co., St. Louis, MO), and with various concen-
trations of CB-01-05 or UFH (4, 20 and 100 IU/ml each).
Dexamethasone (25 mM/ml) was used as positive control.
After incubation, the supernatants were collected and
stored at -80C until cytokines determination. Concen-
tration of IFN-c, TNF-a, interleukin (IL)-2, and IL-10 (pg/
ml) in the supernatants was determined by solid-phase
enzyme-linked immunosorbent assay (ELISA) using com-
mercial kits (Biosource Europe, Nivelles, Belgium),
according to manufacturer’s instructions. To allow statis-
tical evaluation of the data, the samples in which the value
of the cytokine was detected below the limit of sensitivity
of the method were conventionally assigned values
equivalent to this limit (i.e., IFN-c = 21 pg/ml; TNF-a, IL-
2, and IL-10 = 15 pg/ml).
Statistical Analysis
Statistical analysis for significant differences between the
treated groups and the relevant vehicle control groups was
performed according to the Student’s test for unpaired data,
or applying the nonparametric Mann–Whitney test. A value
of P \ 0.05 was considered to be statistically significant.
Results
Experimental Colitis
The results obtained in three independent essays are
expressed as mean values ± standard deviation (SD)
(Table 2), and as percentage reduction/improvement versus
the relevant vehicle control groups (Table 3). The colitis
induction influenced negatively the body growth of the
animals in both the control and the treated groups. In the
vehicle control groups, the intraluminal instillation of DNB
increased the weight of the distal colon more than two
times, as compared with intact animals (historical data
collected in groups of intact animals ranged from
0.76 ± 0.11 to 0.82 ± 0.16 g/10 cm length), and induced
striking macroscopic and histological mucosal damages in
this portion of the colon. All these intestinal DNB-induced
effects were variably influenced by the intracolonic
administration of CB-01-05 and the other reference sub-
stances, so that the profiles of activity of the tested items
greatly differed from each other (Table 2). In particular, as
shown in Table 3 reporting the percentage variations of
activity, CB-01-05 (mean mol. wt. 5,760) was the most
active compound of the series, showing a significant
(P \ 0.01), dose-related percentage reduction of both
colon overweight and mucosal damaged area (MDA), and
also a significant percentage improvement of the histo-
logical score (HS). The effect began from the dose of 0.2
mg, and became fully expressed at the doses of 0.6 and
0.9 mg, which displayed very similar activity. Compared to
CB-01-05, UFH (0.6 mg) resulted about three times less
active on the colon weight, and slightly less effective on
MDA reduction (36% vs. 43%). The other LMWHs
(LMWH-A [mean mol. wt. 5,304], LMWH-B [mean mol.
wt. 3,110], and LMWH-C [mean mol. wt. 2,601]) were
quite ineffective at the tested doses of 0.3–0.6 mg. All
treatments were well tolerated and no obvious effects on
survival rate or macroscopic mucosal haemorrhages were
observed in the animals.
Effect on Cytokines Production by Rat Splenocytes
The results for INF-c, TNF-a, IL-2, and IL-10 production
after 72 h of incubation are reported in Table 4. The
3172 Dig Dis Sci (2008) 53:3170–3175
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stimulation of splenocytes with Con-A or with
PHA + LPS induced a consistent expression of all cyto-
kines which was nearly completely suppressed by
incubation with dexamethasone 25 mM/ml. CB-01-05 and
UFH significantly inhibited (P \ 0.05) IFN-c production
even at the lowest tested concentration. The expression of
TNF-a and IL-10 was only moderately increased by the
incubation with both glycosaminoglycans, whereas IL-2
production was greatly increased by UFH more than four
times the value of the control stimulated group.
Discussion
This study has demonstrated that DNB-induced experi-
mental colitis in rat is a useful and reliable tool to evaluate
the topical anti-inflammatory activity of heparin deriva-
tives, when delivered in direct contact with the mucosa of
the colon. Furthermore it was demonstrated for the first
time that CB-01-05, a LMWH with a mean molecular
weight of about 5,760, when repeatedly applied to the
colonic mucosa, significantly ameliorates the macroscopic
and histological scores of DNB-induced colitis in rat. Our
data are supported by the results previously reported by
Pellequer et al. [10] concerning the efficacy of the rectal
administration of enoxaparin in TNB- and OXA-induced
colitis in mice. Nevertheless, due to the large differences in
the design of the various animal models, a direct compar-
ison of activity between the two LMWHs is not
appropriate. The best anti-inflammatory effect of CB-01-05
was achieved with topical doses ranging from 0.6 to
0.9 mg. Considering that both of these doses displayed
very similar effects, the dose of 0.6 mg could be set as the
best effective dose. This dose is not too far from the dose of















I Control – 239 ± 15.1 223 ± 17.2 1.93 ± 0.3 689.1 ± 138.2 9.1 ± 2.5
CB-01-05 0.005 239 ± 13.0 223 ± 16.1 2.19 ± 0.6 712.1 ± 233.9 9.1 ± 3.0
0.016 246 ± 3.3 228 ± 8.9 1.99 ± 0.2 721.3 ± 67.7 9.0 ± 1.2
0.06 246 ± 4.2 225 ± 15.7 2.10 ± 0.5 653.1 ± 202.0 6.9 ± 1.8
0.2 245 ± 5.3 239 ± 8.8 1.59 ± 0.4 516.0 ± 184.9 5.3 ± 2.4*
0.6 236 ± 17.1 224 ± 16.9 1.50 ± 0.3* 393.6 ± 166.9* 4.0 ± 1.7*
II Control – 240 ± 11.2 225 ± 9.9 1.88 ± 0.4 711.9 ± 137.5 8.4 ± 2.3
CB-01-05 0.3 244 ± 4.9 226 ± 8.3 1.52 ± 0.5 557.3 ± 142.6* 5.5 ± 3.2*
LMWH-A 0.6 242 ± 11.2 231 ± 12.2 1.25 ± 0.2* 382.2 ± 162.1* 4.2 ± 1.41*
LMWH-C 0.9 243 ± 10.6 233 ± 14.7 1.22 ± 0.4* 369.8 ± 185.3* 3.5 ± 2.1*
0.6 238 ± 8.8 225 ± 13.5 1.74 ± 0.5 586.0 ± 183.4 6.0 ± 2.7
0.6 239 ± 9.8 224 ± 6.4 1.85 ± 0.2 524.4 ± 292.5 8.3 ± 1.9
III Control – 242 ± 7.1 218 ± 9.9 1.90 ± 0.20 486.5 ± 106.2 n.a.
LMWH-B 0.3 244 ± 9.7 223 ± 10.2 1.80 ± 0.30 391.8 ± 238.7 n.a.
UFH 0.6 250 ± 6.4 224 ± 8.8 1.80 ± 0.20 420.2 ± 212.3 n.a.
0.6 253 ± 10.1 238 ± 11.6 1.70 ± 0.30 312.5 ± 209.4 n.a.
* P \ 0.01 versus the relevant control group. n.a. = not assessed; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin
Table 3 Effect of CB-01-05, other LMWHs, and UFH in DNB-


















CB-01-05 0.005 0 0 0
0.016 0 0 1
0.06 0 5 24
0.2 18 25 42*
0.3 19 22* 34*
0.6 22* 43* 56*
0.9 35* 48* 58*
LMWH-A 0.6 7 18 28
LMWH-B 0.3 5 19 n.a.
0.6 5 14 n.a.
LMWH-C 0.6 1 26 1
UFH 0.6 10 36 n.a.
* P \ 0.01 versus the relevant control group. n.a. = not assessed;
LMWH = low-molecular-weight heparin; UFH = unfractionated
heparin
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topical budesonide (0.15 mg) which was tested by Palment
et al. [15] in TNB-induced colitis in rat and was found to
be effective. CB-01-05 was also more effective than UFH,
whereas the other evaluated LMWHs (A, B, and C) did not
show noticeable activity at the tested doses. These data
demonstrate that UFH and the various LMWHs assessed
are not biologically equivalent. The evident difference of
anti-inflammatory activity observed among these glycos-
aminoglycans could be in relationship with their different
molecular weight. In fact, it is possible that in the process
of production of LMWHs, obtained by partial hydrolysis or
enzymatic degradation of parent heparin, some of the
biological properties pertaining to UFH [18–21] could be
modified or partially lost. This hypothesis is supported by
the observation that LMWH-A, LMWH-B, and LMWH-C
showed a decreasing activity according to the decrease of
their molecular weight. As a consequence, we believe that
an ideal LMWH proposed for topical use in UC should
have a mean molecular weight not too far from 5,700, as in
the case of CB-01-05. This assumption is further supported
by the recent observation that CB-01-05, orally adminis-
tered to humans as coated colon-release tablets assembled
by the MMXTM technology, was found to be effective and
safe in a pilot study in patients affected by UC [22]. In the
present animal model we did not examine in depth the
mechanism of action underlying the better efficacy of CB-
01-05. Nevertheless, the quick response elicited by CB-01-
05 is predictive for its effect mainly in the acute phase of
the inflammatory process. Our observations made in
splenocytes of untreated rats show that CB-01-05 interferes
with cytokines profile, reducing the production of IFN-c
and increasing the expression of TNF-a, IL-2, and IL-10.
The combined reduction of IFN-c and the increase of IL-10
could account for the observed anti-inflammatory activity
of CB-01-05, considering the pivotal role of IFN-c in
impairing intestinal healing [23], and the well-known
immunoregulatory function of IL-10 [24]. CB-01-05 also
shows a profile of activity different from that of UFH,
resulting more effective as an inhibitor of IFN-c produc-
tion, but consistently less potent in eliciting the release of
TNF-a and, in particular, IL-2. Although the effects of CB-
01-05 on cytokines production are in agreement with the
known ability of dalteparin and other heparin derivatives to
influence cytokines production and to arrest immune
inflammation in rodents [16, 17, 25], we cannot exclude the
involvement of additional mechanisms. Among these
putative mechanisms increase of expression of some
growth factors [26], decrease of nitric oxide synthesis [18,
20, 27], as well as effects on intestinal microcirculation
[12, 28], and leucocyte–endothelial interactions [19] could
be involved in the activity of CB-01-05. On the other hand,
the observation that macroscopic mucosal haemorrhages
were not severer in CB-01-05 group than in the control
groups suggests that the local activity of CB-01-05 is not
mediated by a direct anticoagulant mechanism. These
findings are particularly interesting in term of safety, sug-
gesting that colonic delivery of CB-01-05 should not
increase the risk of intestinal bleeding, as has been
observed with subcutaneous administration of dalteparin in
TNB-induced rat colitis [16].
In conclusion, our data show that CB-01-05 is well
tolerated and, on the contrary to other tested LMWHs,
exerts a potent local anti-inflammatory effect in experi-
mental DNB-induced colitis. Although the precise
mechanism of the anti-inflammatory activity of CB-01-05
is not elucidated in depth, the present data, supported by
the observation that enoxaparin-loaded microspheres is
effective by oral route [10], and by the preliminary
encouraging clinical results obtained with CB-01-05
MMXTM in human UC [22], suggest that CB-01-05, orally
administered in an appropriate colon-release formulation,
is worthy to be assessed in randomized, controlled clinical
trials.
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Table 4 Cytokine release (pg/ml) from rat splenocytes after 72 h of incubation (mean values ± SD)
Treatment Concentration IFN-c TNF-a IL-2 IL-10
(Con-A) (PHA + LPS) (Con-A) (PHA + LPS)
None – 21 ± 0 15 ± 0 15 ± 0 30.5 ± 27
Stimulated control – 7076 ± 2804 61 ± 11 3342 ± 788 183 ± 13
Dexamethasone 25 mM/ml 21 ± 0* 15 ± 0* 15 ± 0* 76 ± 12*
UFH 4 IU/ml 3763 ± 2862* 85 ± 19 4416 ± 568* 193 ± 54
20 IU/ml 3395 ± 2251* 85 ± 18* 9165 ± 1847* 209 ± 88
100 IU/ml 1139 ± 388* 104 ± 35* 14731 ± 3804* 242 ± 55*
CB-01-05 4 IU/ml 3079 ± 1475* 76 ± 14 5512 ± 1442* 168 ± 24
20 IU/ml 3394 ± 1573* 72 ± 17 6404 ± 1002* 229 ± 66
100 IU/ml 986 ± 1447* 81 ± 19* 6414 ± 4808 258 ± 105
* P \ 0.05 versus the relevant stimulated control group. UFH = unfractionated heparin
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